The University of Osaka Hospital

Suita, Osaka 565-0871

15 studies enrolling now · 21 studies all time

What they study most

Advanced Non-Small Cell Lung Cancer, Advanced Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma, Antiphospholipid Syndrome (APS), Aortic Valve Stenosis, Behçet's Syndrome (BS), Biochemically Recurrent Prostate Cancer, Breast Cancer, Breast Neoplasms, Bullous Pemphigoid (BP), Cachexia, Cancer

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting now
• Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) — Recruiting now
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer — Recruiting now
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. — Recruiting now
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) — Recruiting now
• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer — Recruiting now
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer — Recruiting now
• S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB — Recruiting now
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies — Running, not enrolling
• Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients — Running, not enrolling
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling